10.31.19
Parexel has expanded its collaboration with the Society for Clinical Research Sites (SCRS), a global organization dedicated to representing the interests of clinical research sites. The company will participate as a Site Engagement Partner and lead a number of key initiatives focused on improving the patient experience in clinical trials, which plays an important role in bringing new therapies to market. Parexel’s Global Site Solutions team maintains a Site Alliance Network of more than 500 sites and 17,100 investigators across the globe.
“In clinical development, patient engagement is critical to success and investigative sites play an important role in enhancing engagement with patients,” said Gadi Saarony, Executive Vice President and Chief Clinical Research Services Officer, Parexel. "Parexel shares SCRS’ commitment to alignment among sites, patients and customers and is honored to play an active role in driving key initiatives that ultimately will improve the experience for patients."
With this collaboration, Parexel will work with SCRS on several new initiatives. Parexel will lead a Site Advocacy Group (SAG) aimed at diminishing patient burden in clinical trials, bringing sites and patients together to discuss patient perceptions of methods of reduction of patient encumbrance to participate in clinical trials.
Also, Parexel will join the SCRS Diversity Initiative to help address challenges and opportunities at the site level while exploring the needs of diverse patient populations in clinical research participation across the globe, alongside leading global biopharmaceutical partners.
“We are delighted to partner with Parexel on these important site initiatives,” said Casey Orvin, President, SCRS. “Our organization has a longstanding track record of bringing together the key stakeholders involved in the drug development process to collaborate in new and different ways to address the toughest challenges in drug development. We look forward to working with Parexel to advance these important initiatives.”
“In clinical development, patient engagement is critical to success and investigative sites play an important role in enhancing engagement with patients,” said Gadi Saarony, Executive Vice President and Chief Clinical Research Services Officer, Parexel. "Parexel shares SCRS’ commitment to alignment among sites, patients and customers and is honored to play an active role in driving key initiatives that ultimately will improve the experience for patients."
With this collaboration, Parexel will work with SCRS on several new initiatives. Parexel will lead a Site Advocacy Group (SAG) aimed at diminishing patient burden in clinical trials, bringing sites and patients together to discuss patient perceptions of methods of reduction of patient encumbrance to participate in clinical trials.
Also, Parexel will join the SCRS Diversity Initiative to help address challenges and opportunities at the site level while exploring the needs of diverse patient populations in clinical research participation across the globe, alongside leading global biopharmaceutical partners.
“We are delighted to partner with Parexel on these important site initiatives,” said Casey Orvin, President, SCRS. “Our organization has a longstanding track record of bringing together the key stakeholders involved in the drug development process to collaborate in new and different ways to address the toughest challenges in drug development. We look forward to working with Parexel to advance these important initiatives.”
